A temperature-sensitive medicine does not care how big your network is. It cares whether the box stayed between two and eight degrees from the factory door to the hospital shelf, every handover, every tarmac wait, every hour in the hold. That is why the quiet news out of Bonn this month matters more than its modest headline suggests. On 12 October 2026, DHL Global Forwarding opened six new dedicated Life Sciences & Healthcare air corridors, extending its Cold Chain Network deep into Asia’s pharmaceutical markets. For shippers of pharma, biologics, vaccines and clinical-trial materials, it is genuinely good news: more validated, temperature-controlled lift on some of the most important healthcare lanes in the world. But it also carries a lesson that sits right at the centre of how ACC thinks about freight, because capacity that belongs to one operator is only ever as useful as the day your shipment fits it.
What DHL actually launched
The announcement adds six corridors to DHL’s Cold Chain Network, building on the Brussels to Cincinnati corridor the company opened earlier in 2026.
The six new lanes are:
- Liège to Shanghai: a Benelux gateway straight into China’s commercial pharma hub.
- Brussels to Shanghai: a second Belgian origin into Shanghai.
- Brussels to Singapore: connecting Belgium to Southeast Asia’s healthcare gateway.
- Cincinnati to Singapore: a North American hub into Singapore.
- Cincinnati to Tokyo Narita: into Japan.
- Cincinnati to Seoul Incheon: into South Korea.
The corridors carry temperature-sensitive healthcare shipments, pharmaceuticals, biologics, vaccines and clinical-trial materials, on a network built from dedicated lanes, validated handling procedures, specialised thermal-blanket solutions and temperature-controlled infrastructure. DHL notes that most flights run on its own aircraft, and that its Boeing 777 freighters carry three compartments each with separately set temperatures. On the ground, the planned Singapore Cold Chain Hub will offer 2 to 8°C and 15 to 25°C storage and handling with direct airside access, while Indianapolis is adding 2 to 8°C floorspace for operations and pallet storage.
Henk Venema, Global Head of Air Freight at DHL Global Forwarding, put the strategic intent plainly: “These new corridors further expand our Cold Chain Network into strategically important healthcare markets across Asia. They respond to customer demand for reliable connectivity between major healthcare markets, while giving us greater control over critical quality parameters throughout the transportation process. This enables our customers to move critical healthcare products with greater confidence and reliability.”
Why pharma is the lane everyone is fighting over
Pharma is not just another commodity in the hold. It is a premium, zero-tolerance category: a single temperature excursion can turn a six-figure consignment into a write-off and a patient-supply problem. That combination, high value, high stakes, strict regulatory handling, is exactly why carriers and forwarders are investing hard in cold-chain capability, and why temperature-controlled lane capacity is some of the most contested in air cargo.
For the shipper, the attraction of a dedicated corridor is obvious. Fewer handovers mean fewer points where the chain can break. A validated lane with known handling and known infrastructure means a product that arrives in specification, with the paperwork to prove it. When DHL says most of these flights run on its own aircraft, reducing handovers and giving it more control, it is describing a real quality advantage, not marketing gloss.
The trade-off hidden inside “our own aircraft”
Here is the part worth reading twice. The same feature that makes a dedicated corridor reliable, one operator, one network, one set of aircraft, is also what narrows it. A corridor is superb when your shipment, your lane and your departure day line up with it. It does far less for you when they do not.
Consider the practical limits:
- Your lane may not be on the map. Six new corridors are six specific city pairs. A pharma shipment from, say, Amsterdam to Bangkok, or from a secondary European manufacturing site into India, sits outside this particular grid, and a network’s instinct is to route you through its hubs, not necessarily by the shortest, coolest path for your box.
- Your day may not match the rotation. Dedicated freighter corridors run to a schedule. If your release date falls between departures, “reliable connectivity” can still mean waiting, and for a clinical-trial batch or a vaccine lot, waiting is a risk, not an inconvenience.
- One operator means one answer. When capacity belongs to the party selling you the move, the recommended routing is, understandably, that party’s routing. There is nothing wrong with that, but it is not the same thing as the best routing for your specific shipment on that specific day.
None of this is a criticism of DHL’s investment, which is substantial and welcome. It is simply the nature of any single network: it is built to be filled.
This reshapes capacity right on ACC’s doorstep
Two of the six new origins are Liège and Brussels, Benelux gateways at the heart of ACC’s home market. That is not a coincidence. Belgium’s airports have become serious pharma hubs precisely because the region concentrates manufacturing, handling expertise and freighter capacity, and because gateways such as Liège and Brussels have invested in the cold-chain infrastructure that healthcare freight demands.
For shippers moving pharma through the Benelux, that means the capacity picture on your doorstep is shifting again, more dedicated temperature-controlled lift into Asia, but concentrated on specific lanes and a specific operator. The right response is not to default to it, nor to ignore it, but to weigh it against everything else flying your lane.
How a neutral broker reads a move like this
As a neutral broker, ACC has no hub and no corridor that needs filling. That is the whole point. When a major network adds capacity, ACC’s job is to treat it as one more option on the board, a strong one on the right lane, and to measure it against every alternative for your actual shipment.
In practice that means:
- Weighing every pharma-capable carrier, not one. Air France-KLM, Lufthansa, Qatar Airways, Emirates, Cathay, Turkish and others all run serious cold-chain products; the best fit depends on your lane, your volume and your timing, not on whose corridor you happen to be offered.
- Matching the temperature solution to the risk. Active containers, passive thermal blankets and phase-change materials each suit different lanes and durations; a neutral view picks the solution that keeps the product in spec, rather than the one a single network happens to standardise on.
- Planning the gateway on the merits. Liège, Brussels, Amsterdam, Frankfurt and others each have different handling strengths, cut-off times and onward connectivity for healthcare freight, and the shortest, coldest path is not always the obvious one.
- Keeping a second option warm. For product that cannot tolerate a missed connection, optionality is not a luxury; it is part of the quality plan.
More cold-chain capacity in the market is a good thing for every pharma shipper. Using it well is a different skill, and that is the one worth buying.
The bottom line
DHL’s six new corridors add real, validated temperature-controlled capacity on important healthcare lanes, with two of the six running from ACC’s Benelux home market. That is good news. But a dedicated corridor is reliable when your lane and your day match it, and a constraint when they do not, and the party selling you the move will always, reasonably, recommend its own network. For pharma, where a single excursion can cost a batch, the decisive question is not whose corridor is biggest. It is which carrier, which gateway and which temperature solution keeps your specific product in specification, on your specific day.
Shipping pharma, biologics or other temperature-critical freight to or from Europe? ACC will map your lanes across every pharma-capable carrier and gateway, match the temperature solution to the risk, and keep a validated alternative ready for the day your first choice is not available. Talk to ACC before you commit your cold chain to a single corridor.
Sources: DHL Group press release, “DHL Global Forwarding expands cold chain network with six new air corridors” (DHL Global Forwarding, Bonn, 12 October 2026); STAT Times, “DHL adds six healthcare air cargo corridors connecting Asia” (13 October 2026).
